search
Back to results

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A

Primary Purpose

Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation, Euploid Rate

Status
Recruiting
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
GnRH antagonist
oral Duphaston
Sponsored by
ShangHai Ji Ai Genetics & IVF Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Preimplantation Genetic Testing

Eligibility Criteria

20 Years - 43 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Age of women <43 years at the time of ovarian stimulation for IVF
  • Antral follicle count (AFC) >=5 on day 2-5 of the period
  • PGT-A indicated for advanced maternal age (>=38 years), recurrent miscarriage (>=2 consecutive miscarriage) and repeated implantation failure (>=4 embryos replaced or >=2 blastocysts replaced without success), recurrent foetal aneuploidy

Exclusion Criteria:

  • Presence of a functional ovarian cyst with E2>100 pg/mL
  • Recipient of oocyte donation
  • Presence of hydrosalpinx or endometrial polyp which is not surgically treated

Sites / Locations

  • Shanghai JiAi Genetics & IVF InstituteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Antagonist group

PPOS group

Arm Description

Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.

Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger.

Outcomes

Primary Outcome Measures

euploidy rate
euploidy rate of blastocysts

Secondary Outcome Measures

number of mature oocytes
number of MII oocytes
number and grading of blastocysts
number and grading of blastocysts suitable for biopsy and freezing
positive serum hCG
serum β-hCG ≥10 mIU/mL of the first FET
clinical pregnancy
presence of intrauterine gestational sac by trans-vaginal ultrasound at 6 gestational weeks of the first FET
implantation rate
the number of gestational sacs per blastocyst transferred of the first FET
biochemical pregnancy
positive serum hCG not followed by clinical pregnancy of the first FET
ongoing pregnancy
a viable pregnancy beyond 12 weeks' gestation of the first FET
live birth rate
deliveries ≥22 weeks gestation with heartbeat and breath of the first FET
multiple pregnancy
more than one intrauterine sacs on scanning
ectopic pregnancy
pregnancy outside the uterine cavity
birthweight of newborns
the birth weight of newborns
serum baseline FSH
baseline FSH of period day 2-3
progesterone level on the trigger day
progesterone level on the trigger day
estradiol level on the trigger day
estradiol level on the trigger day
miscarriage
clinically recognised pregnancy loss before 22 weeks of pregnancy.

Full Information

First Posted
May 25, 2020
Last Updated
April 21, 2023
Sponsor
ShangHai Ji Ai Genetics & IVF Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04414748
Brief Title
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A
Official Title
A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the Progestin-primed Ovarian Stimulation Protocol and the GnRH Antagonist Protocol in Patients Undergoing PGT-A
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 10, 2020 (Actual)
Primary Completion Date
December 1, 2023 (Anticipated)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ShangHai Ji Ai Genetics & IVF Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This randomized trial aims to compare the euploid rate of blastocysts between PPOS and GnRH antagonist protocols in patients undergoing PGT-A. Infertile women who have medical indication for PGT-A will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preimplantation Genetic Testing, Progestin-primed Ovarian Stimulation, Euploid Rate, GnRH Antagonist

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
400 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Antagonist group
Arm Type
Active Comparator
Arm Description
Women will receive antagonist (Cetrotide 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
Arm Title
PPOS group
Arm Type
Experimental
Arm Description
Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger.
Intervention Type
Drug
Intervention Name(s)
GnRH antagonist
Other Intervention Name(s)
Cetrorelix
Intervention Description
GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of COH till the day of the ovulation trigger
Intervention Type
Drug
Intervention Name(s)
oral Duphaston
Other Intervention Name(s)
Duphaston
Intervention Description
oral Duphaston 10mg bd from Day 3 of COH till the day of ovulation trigger.
Primary Outcome Measure Information:
Title
euploidy rate
Description
euploidy rate of blastocysts
Time Frame
1 month after oocyte retrieval
Secondary Outcome Measure Information:
Title
number of mature oocytes
Description
number of MII oocytes
Time Frame
1 day after oocyte retrieval
Title
number and grading of blastocysts
Description
number and grading of blastocysts suitable for biopsy and freezing
Time Frame
1 week after oocyte retrieval
Title
positive serum hCG
Description
serum β-hCG ≥10 mIU/mL of the first FET
Time Frame
2 weeks after FET
Title
clinical pregnancy
Description
presence of intrauterine gestational sac by trans-vaginal ultrasound at 6 gestational weeks of the first FET
Time Frame
6 weeks' gestation
Title
implantation rate
Description
the number of gestational sacs per blastocyst transferred of the first FET
Time Frame
6 weeks' gestation
Title
biochemical pregnancy
Description
positive serum hCG not followed by clinical pregnancy of the first FET
Time Frame
6 weeks' gestation
Title
ongoing pregnancy
Description
a viable pregnancy beyond 12 weeks' gestation of the first FET
Time Frame
12 weeks' gestation
Title
live birth rate
Description
deliveries ≥22 weeks gestation with heartbeat and breath of the first FET
Time Frame
1 year after FET
Title
multiple pregnancy
Description
more than one intrauterine sacs on scanning
Time Frame
multiple pregnancy beyond gestation 12 weeks
Title
ectopic pregnancy
Description
pregnancy outside the uterine cavity
Time Frame
ectopic pregnancy during 12 weeks' gestation
Title
birthweight of newborns
Description
the birth weight of newborns
Time Frame
1 year after FET
Title
serum baseline FSH
Description
baseline FSH of period day 2-3
Time Frame
day 2-3 of period
Title
progesterone level on the trigger day
Description
progesterone level on the trigger day
Time Frame
2 days before oocyte retrieval
Title
estradiol level on the trigger day
Description
estradiol level on the trigger day
Time Frame
2 days before oocyte retrieval
Title
miscarriage
Description
clinically recognised pregnancy loss before 22 weeks of pregnancy.
Time Frame
22 weeks of pregnancy

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
43 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age of women <43 years at the time of ovarian stimulation for IVF Antral follicle count (AFC) >=5 on day 2-5 of the period PGT-A indicated for advanced maternal age (>=38 years), recurrent miscarriage (>=2 consecutive miscarriage) and repeated implantation failure (>=4 embryos replaced or >=2 blastocysts replaced without success), recurrent foetal aneuploidy Exclusion Criteria: Presence of a functional ovarian cyst with E2>100 pg/mL Recipient of oocyte donation Presence of hydrosalpinx or endometrial polyp which is not surgically treated
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
HE LI, MD
Phone
+8613817223099
Email
lihe198900@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
XIAOXI SUN, PHD
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
XIAOXI SUN, PHD
Organizational Affiliation
Shanghai JiAi Genetics & IVF Institute
Official's Role
Study Director
Facility Information:
Facility Name
Shanghai JiAi Genetics & IVF Institute
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200011
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
HE LI, MD
Phone
+8602163459977
Email
lihe198900@163.com

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data that underlie the results after deidentification (text, tables, figures, and appendices) and study protocol will be shared.
IPD Sharing Time Frame
Data will be available when beginning 3 months and ending 5 years following article publication.
IPD Sharing Access Criteria
To achieve aims in the approved proposal, researchers who provide a methodologically sound proposal will be shared with. Proposals should be sent to lihe198900@163.com.
Citations:
PubMed Identifier
25432917
Citation
Lee E, Illingworth P, Wilton L, Chambers GM. The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. Hum Reprod. 2015 Feb;30(2):473-83. doi: 10.1093/humrep/deu303. Epub 2014 Nov 28.
Results Reference
background
PubMed Identifier
30927417
Citation
Begueria R, Garcia D, Vassena R, Rodriguez A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod. 2019 May 1;34(5):872-880. doi: 10.1093/humrep/dez034.
Results Reference
background
PubMed Identifier
29300975
Citation
Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Quan X, Lyu Q, Kuang Y, Ai A. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018 Feb 1;33(2):229-237. doi: 10.1093/humrep/dex367.
Results Reference
background
PubMed Identifier
28062551
Citation
Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017 Mar 1;23(2):211-220. doi: 10.1093/humupd/dmw047.
Results Reference
background
PubMed Identifier
25956370
Citation
Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022. Epub 2015 May 5.
Results Reference
background

Learn more about this trial

Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A

We'll reach out to this number within 24 hrs